Investor presentation
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
Investor presentation
London, UK, 30 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Tim Watts, Chief Executive Officer, will present at the Proactive One2One Virtual Investor Forum on Thursday 8 April 2021.
Shield will be one of three companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place from 6.00pm. Investors can register to attend here:
https://event.webinarjam.com/register/1024/gwwg2hxq9
No new material information will be disclosed at the event and t he presentation will be made available on the Company's website shortly after the event here: https://www.shieldtherapeutics.com/investors/presentations
For further information, please contact:
|
Shield Therapeutics plc |
+44 (0) 191 511 8500 |
||
|
Tim Watts (CEO) |
|
||
|
|
|
||
|
Peel Hunt LLP - Nominated Adviser and Joint Broker |
+44 (0) 20 7148 8900 |
||
|
James Steel / Christopher Golden |
|
||
|
|
|
||
|
finnCap Ltd - Joint Broker |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / Alice Lane / Matthew Radley |
|
||
|
|
|
||
|
Walbrook PR - Financial PR & IR Adviser |
+44 (0) 20 7933 8780 |
||
|
Paul McManus / Lianne Cawthorne |
or shield@walbrookpr.com |
||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 19 minutes ago Luceco
- 20 minutes ago Finsbury Growth & Income Trust
- 1 hour ago Big Yellow Group
- 2 hours ago Smith & Nephew
- 2 hours ago Pennon Group